Advances in bone marrow-derived cell therapy: CD31-expressing cells as next generation cardiovascular cell therapy

Sung Whan Kim, Hyongbum Kim, Youngsup Yoon

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

In the past few years, bone marrow (BM)-derived cells have been used to regenerate damaged cardiovascular tissues post-myocardial infarction. Recent clinical trials have shown controversial results in recovering damaged cardiac tissue. New progress has shown that the underlying mechanisms of cell-based therapy relies more heavily on humoral and paracrine effects rather than on new tissue generation. However, studies have also reported the potential of new endothelial cell generation from BM cells. Thus, efforts have been made to identify cells having higher humoral or therapeutic effects as well as their surface markers. Specifically, BM-derived CD31+ cells were isolated by a surface marker and demonstrated high angio-vasculogenic effects. This article will describe recent advances in the therapeutic use of BM-derived cells and the usefulness of CD31+ cells.

Original languageEnglish
Pages (from-to)335-349
Number of pages15
JournalRegenerative Medicine
Volume6
Issue number3
DOIs
Publication statusPublished - 2011 May 1

Fingerprint

Cell- and Tissue-Based Therapy
Bone Marrow Cells
Bone
Therapeutic Uses
Tissue
Endothelial cells
Endothelial Cells
Bone Marrow
Myocardial Infarction
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Biomedical Engineering
  • Embryology

Cite this

@article{e8bb0185e9a34e1b86a2e846ba4d5974,
title = "Advances in bone marrow-derived cell therapy: CD31-expressing cells as next generation cardiovascular cell therapy",
abstract = "In the past few years, bone marrow (BM)-derived cells have been used to regenerate damaged cardiovascular tissues post-myocardial infarction. Recent clinical trials have shown controversial results in recovering damaged cardiac tissue. New progress has shown that the underlying mechanisms of cell-based therapy relies more heavily on humoral and paracrine effects rather than on new tissue generation. However, studies have also reported the potential of new endothelial cell generation from BM cells. Thus, efforts have been made to identify cells having higher humoral or therapeutic effects as well as their surface markers. Specifically, BM-derived CD31+ cells were isolated by a surface marker and demonstrated high angio-vasculogenic effects. This article will describe recent advances in the therapeutic use of BM-derived cells and the usefulness of CD31+ cells.",
author = "Kim, {Sung Whan} and Hyongbum Kim and Youngsup Yoon",
year = "2011",
month = "5",
day = "1",
doi = "10.2217/rme.11.24",
language = "English",
volume = "6",
pages = "335--349",
journal = "Regenerative Medicine",
issn = "1746-0751",
publisher = "Future Medicine Ltd.",
number = "3",

}

Advances in bone marrow-derived cell therapy : CD31-expressing cells as next generation cardiovascular cell therapy. / Kim, Sung Whan; Kim, Hyongbum; Yoon, Youngsup.

In: Regenerative Medicine, Vol. 6, No. 3, 01.05.2011, p. 335-349.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Advances in bone marrow-derived cell therapy

T2 - CD31-expressing cells as next generation cardiovascular cell therapy

AU - Kim, Sung Whan

AU - Kim, Hyongbum

AU - Yoon, Youngsup

PY - 2011/5/1

Y1 - 2011/5/1

N2 - In the past few years, bone marrow (BM)-derived cells have been used to regenerate damaged cardiovascular tissues post-myocardial infarction. Recent clinical trials have shown controversial results in recovering damaged cardiac tissue. New progress has shown that the underlying mechanisms of cell-based therapy relies more heavily on humoral and paracrine effects rather than on new tissue generation. However, studies have also reported the potential of new endothelial cell generation from BM cells. Thus, efforts have been made to identify cells having higher humoral or therapeutic effects as well as their surface markers. Specifically, BM-derived CD31+ cells were isolated by a surface marker and demonstrated high angio-vasculogenic effects. This article will describe recent advances in the therapeutic use of BM-derived cells and the usefulness of CD31+ cells.

AB - In the past few years, bone marrow (BM)-derived cells have been used to regenerate damaged cardiovascular tissues post-myocardial infarction. Recent clinical trials have shown controversial results in recovering damaged cardiac tissue. New progress has shown that the underlying mechanisms of cell-based therapy relies more heavily on humoral and paracrine effects rather than on new tissue generation. However, studies have also reported the potential of new endothelial cell generation from BM cells. Thus, efforts have been made to identify cells having higher humoral or therapeutic effects as well as their surface markers. Specifically, BM-derived CD31+ cells were isolated by a surface marker and demonstrated high angio-vasculogenic effects. This article will describe recent advances in the therapeutic use of BM-derived cells and the usefulness of CD31+ cells.

UR - http://www.scopus.com/inward/record.url?scp=79955870166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955870166&partnerID=8YFLogxK

U2 - 10.2217/rme.11.24

DO - 10.2217/rme.11.24

M3 - Review article

C2 - 21548739

AN - SCOPUS:79955870166

VL - 6

SP - 335

EP - 349

JO - Regenerative Medicine

JF - Regenerative Medicine

SN - 1746-0751

IS - 3

ER -